Real-world evidence solutions

Truveta’s patient-level health data empowers researchers to generate evidence to drive product innovation and clinical advancements

How we can help

Clinical trials

Accelerate clinical trial timelines by enrolling the right patients faster, with direct access to community health systems.

Clinical trials are costly, and only 9.6% of drugs and 45% of devices are approved. Truveta enables life sciences companies to:

  • De-risk clinical programs by optimizing trial design 
  • Recruit faster and more equitably with Truveta’s health system network
  • Generate robust evidence using real-world control arms

Testing I/E criteria to de-risk clinical programs

Diagram detailing inclusion and exclusion criteria applied to a heart failure population. The criteria encompass medication use, length of stay, outpatient encounters, laboratory results, comorbidities, and device use. The visual representation offers a comprehensive overview of the selection criteria, aiding in understanding the parameters used to define the study population.

Sample heart failure population with inclusion/exclusion criteria applied

Safety monitoring

Fulfill post-market safety requirements at half the cost and twice as fast with regulatory-grade data.

Post-approval safety studies are costly, as are the consequences of delayed signal detection. Truveta enables life sciences companies to:

  • Replace expensive and long-running registries 
  • Meet regulatory evidence standards faster and at lower cost 
  • Assess the validity of potential safety signals in real-time

 

Tracking adverse events post-vaccination

Dashboard showing adverse events by demographic, manufacturer, comorbidity, dose, and more within Truveta Studio

Comparative effectiveness

Establish product differentiation and increase market adoption with timely patient-level outcomes and SDOH data.

The absence of real-world outcomes data may result in reduced clinician confidence and product adoption. Truveta enables life sciences to:

  • Generate evidence of differentiated clinical outcomes
  • Understand real-world product performance for specific subpopulations 
  • Ensure the right patients have access to therapies

 

Comparing outcomes of novel interventions

Comparison table from a scientific publication illustrating bleeding events associated with two medical devices for treating pulmonary embolism: the USCDT (Unspecified Superiority Clot Dissolver) and MT (Standard Mechanical Thrombectomy). The data is presented for two distinct time periods—2009 to 2023 (primary analysis) and 2018 to 2023 (contemporary analysis). Bleeding events are categorized into six types, with results presented as counts and percentages. Statistical significance is indicated by p-values, providing insights into the safety profiles of the two devices over time.

Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

Label expansion

Identify emerging opportunities to expand product usage and improve care with timely patient-level outcomes data.

Missed label expansion opportunities may result in unmet patient needs and limit R&D ROI. Truveta enables life sciences companies to:

  • Understand real-world product use with full clinical context 
  • Produce regulatory-grade evidence for label expansion
  • Replace clinical studies with long lead times

Monitoring on- and off-label prescribing patterns

Stacked line chart depicting trends in on-and off-label GLP-1 prescribing for first-time prescriptions, categorized by indication: type 2 Diabetes and obesity. The type 2 diabetes graph illustrates prescribing patterns for four specific drugs between January 2018 and April 2023, while the obesity graph displays data for two drugs. The y-axis represents the number of prescriptions, showcasing variations in prescribing practices for GLP-1 drugs for both medical conditions.

First-time GLP-1 prescriptions by medication by labeled indication and on- and off-label use

Closing care gaps

 Collaborate with health systems to advance adoption of insights into patient care.

Suboptimal treatment patterns and ineffective care coordination drive poorer health outcomes and significant avoidable costs. Truveta’s unique relationship with community health systems enables life sciences companies to:

  • Accelerate discoveries by streamlining evidence generation
  • Partner on novel data collection to understand current clinical context
  • Collaborate on groundbreaking research to improve patient outcomes

Assessing the clinical consequences of diagnostic delays

Table displaying diagnoses of depression, anxiety, substance use disorder, or surgery for abscess, cyst, or boils before the primary diagnosis, Hidradenitis Suppurativa (HS), categorized by the length of HS diagnostic delay - short, medium, and long. The results present counts within each diagnostic delay category, alongside the number and percentage of individuals with each additional diagnosis or event. This analysis provides insights into the associations between diagnostic delays and the occurrence of specific health conditions or events prior to the primary diagnosis.

Rates of mental health diagnoses and surgery by length of HS diagnostic delay

How we can help

Clinical trials

Safety monitoring

Comparative effectiveness

Label expansion

Closing care gaps

Clinical trials

Accelerate clinical trial timelines and speed time to market by identifying the right patients faster.

Clinical trials are costly, and only 9.6% of drugs and 45% of devices are approved. Truveta enables life sciences companies to:
^
De-risk clinical programs by optimizing trial design
^
Build and analyze populations with direct access to Truveta’s health system network
^
Generate robust evidence using real-world control arms
Testing I/E criteria to de-risk clinical programs
October 2023 Respiratory Viruses hospitalizations trend report
Sample heart failure population with inclusion/exclusion criteria applied
Read the webinar recap

Safety monitoring

Fulfill post-market safety requirements at half the cost and twice as fast with regulatory-grade data.

Post-approval safety studies are costly, as are the consequences of delayed signal detection. Truveta enables life sciences companies to:
^
Replace expensive and long-running registries 
^
Meet regulatory evidence standards faster and at lower cost
^
Assess the validity of potential safety signals in real-time
Tracking adverse events post-vaccination
October 2023 Respiratory Viruses hospitalizations trend report
Dashboard showing adverse events by demographic, manufacturer, comorbidity, dose, and more within Truveta Studio

Comparative effectiveness

Establish product differentiation and increase market adoption with timely patient-level outcomes and SDOH data.

The absence of real-world outcomes data may result in reduced clinician confidence and product adoption. Truveta enables life sciences to:
^
Generate evidence of differentiated clinical outcomes
^
Understand real-world product performance for specific subpopulations
^
Ensure the right patients have access to therapies
Comparing outcomes of novel interventions
October 2023 Respiratory Viruses hospitalizations trend report
Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions
Read the research

Label expansion

Identify emerging opportunities to expand product usage and improve care with timely patient-level outcomes data.

Missed label expansion opportunities may result in unmet patient needs and limit R&D ROI. Truveta enables life sciences companies to:
^
Understand real-world product use with full clinical context
^
Produce regulatory-grade evidence for label expansion
^
Replace clinical studies with long lead times
Monitoring on- and off-label prescribing patterns
October 2023 Respiratory Viruses hospitalizations trend report
First-time GLP-1 prescriptions by medication by labeled indication and on- and off-label use
Read the research

Closing care gaps

Collaborate with health systems to advance adoption of insights into patient care.

Suboptimal treatment patterns and ineffective care coordination drive poorer health outcomes and significant avoidable costs. Truveta’s unique relationship with community health systems enables life sciences companies to:
^
Partner on novel data collection to understand current clinical context
^
Collaborate on groundbreaking research to improve patient outcomes
^
Accelerate discoveries by streamlining evidence generation
Assessing the clinical consequences of diagnostic delays
October 2023 Respiratory Viruses hospitalizations trend report
Rates of mental health diagnoses and surgery by length of HS diagnostic delay
Read the webinar recap

Learn why top pharmaceutical and med device companies use Truveta to:

  • Drive better healthcare strategies with the most complete picture of US health
  • Make decisions ahead of the competition with data that's refreshed daily
  • Unlock meaningful insights from clinical notes and medical images
  • Boost collaboration with seamless data analytics for the entire team
  • Let’s work together to improve patient outcomes with data.

Let’s chat